title: Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice.
abstract: We studied the efficacy of telithromycin in Haemophilus influenzae pneumoniae in three different age groups of mice. Pneumonia was produced by endotracheal instillation of 1 x 10(4) CFU/ml of bacteria and treatment was initiated with saline for control and compared with two different doses, 50 and 100 mg/kg per BID telithromycin twice a day for 1 week. For comparison, we used erythromycin (ERY) and clarithromycin (CLA), both given twice a day at 50 mg/kg per BID. Some animals were euthanized on the third or 7th day of therapy and their lung tissue was cultured for bacteria. Presence of bacteria was considered a failure and a sterile lung was considered cured. As expected, about one half of middle-aged animals (8-10 months) were cured on saline. In contrast, almost none of the young (2-3 weeks) and old animals (18-20 months) were cured without antibiotic therapy. Among the young, the cure rates with telithromycin, ERY and CLA were 81, 50 and 33%, respectively. Of the senescent mice, the cure rate with ERY was 50% whereas the rates with CLA and telithromycin (50 mg/kg) were 62 and 75%, respectively. In conclusion, telithromycin is effective against H. influenzae at both extremes of life.
authors.affiliation: Division of Geriatrics/Gerontology, Charles Drew University of Science and Medicine, UCLA and UCI School of Medicine, 1731 E 120th St Los Angeles, CA 90059, USA. svgallop@uci.edu
authors.forename: Haragopal
authors.initials: H
authors.lastname: Thadepalli
authors.forename: See Kean
authors.initials: SK
authors.lastname: Chuah
authors.forename: Lucy
authors.initials: L
authors.lastname: Iskandar
authors.forename: Sastry
authors.initials: S
authors.lastname: Gollapudi
mesh_terms: D000375:Aging / Q000502:physiology*; D000818:Animals; D000833:Animals, Suckling; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000032:analysis / Q000097:blood / Q000627:therapeutic use*; D019540:Area Under Curve; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D004917:Erythromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D006193:Haemophilus influenzae; D048628:Ketolides; D008168:Lung / Q000382:microbiology; D018942:Macrolides; D051379:Mice; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; D004917:Erythromycin; D017291:Clarithromycin; C106791:telithromycin